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Abstract 
Schistosomiasis is a parasitic disease that leads to chronic ill-health. Infection is acquired from infested 
freshwater containing the larval forms (cercariae) of blood flukes, known as schistosomes. The three main 
species of the parasite that infect humans are Schistosoma haematobium, S.japonicum, and S.mansoni. 
Schistosomiasis affects at least 230 million people worldwide. The infection is prevalent in tropical and sub-
tropical areas, in poor communities without potable water and adequate sanitation. The disease is considered as 
one of the Neglected Tropical Diseases and so far praziquantel is the only drug used for treatment. Should the 
parasites develop resistance to praziquantel, treatment would be problematic.  This study incorporated a 
computational approach to design novel compounds with unprecedented potential as candidate drug compounds 
for the disease. The Schistosoma mansoni fatty acid binding protein was selected as a suitable drug target for its 
crucial role in the dependence of the parasite on its host for fatty acids. Screening for potential lead compounds 
was done using molecular docking software.  Identified lead compounds were analyzed and optimized in silico 
for their ADMET properties then re-evaluated for suitability of their binding energies. Eight novel compounds 
with good predicted ADMET properties were designed and found to interact with the S.mansoni fatty acid 
binding protein with favorable binding energy, showing potential to inhibit this protein. This study opens up new 
possibilities in antischistosomal drug inquiry and potentiates efficacy studies of such compounds against 
schistosomiasis. 
Keywords: computational design, antischistosomal drug inquiry, binding energy, lead optimization, ADMET 
properties  
 
1. Introduction 
Among human parasitic diseases, schistosomiasis also called bilharziasis ranks second after malaria in terms of 
socio-economic and public health importance in tropical and subtropical areas with more than 700 million people 
at risk (Steinman et al., 2006). The most common way of infection with schistosomiasis in developing countries 
is by wading or swimming in water bodies that are infested with snails usually of the genera Biomphalaria, 
Bulinus, or Oncomelania which are the natural reservoirs of the Schistosoma pathogen. 
 Praziquantel is the recommended treatment for schistosomiasis at 40 mg/kg body weight per dose 
according to the World Health Organization’s factsheet. Reliance on a single drug to treat a population of over 
200 million people infected and over 700 million people at risk over three continents (Steinman et al., 2006) 
seems particularly perilous when considering the threat of drug resistance. 
 Although widespread resistance to praziquantel has not been reported, cases of reduced susceptibility to 
praziquantel by schistosomes have been reported. In a study in Kisumu, Kenya, schistosomal isolates from 
patients that had previously been treated with praziquantel were found to be less susceptible to praziquantel than 
isolates from previously untreated patients (Melman et al., 2009). Resistance to the drug has been shown to be 
inducible in vitro (Couto et al., 2011) and therefore a growing concern whether resistance may develop and 
spread. 
 The Schistosoma Genome Network has published the S.mansoni genome sequenced using whole 
genome shotgun sequencing by the Pathogen Genomics group at the Wellcome Trust Sanger Institute (Berriman 
et al., 2009). Availability of genomic datasets has facilitated the identification and prioritization of drugs and 
drug targets in several neglected tropical disease pathogens (Crowther et al., 2010). Similarly, availability of this 
information has enabled development of new tools and resources for understanding the parasite’s biological 
systems. This study makes use of manually drawn S.mansoni metabolic pathway maps in the Kyoto 
Encyclopedia of Genes and Genomes (KEGG) database (Kanehisa et al., 2012) to propose a putative drug target 
for the parasite and employs a computational approach to design candidate inhibitor compounds for the target as 
a plausible input in the drug development process for schistosomiasis.  
 
2. Materials and Methods 
2.1 Target selection  
S.mansoni metabolic pathway maps were accessed at the KEGG website and used to identify several proteins 
that play crucial roles in the parasite’s metabolism. These proteins were selected for their likelihood to disrupt 
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their respective metabolic pathways if inhibited through drug targeting.  
 
2.2 Target validation 
The presence of experimentally determined structures of the proteins was used as a criterion for target validation. 
Only proteins with structures in the Protein Data Bank (PDB) (Berman et al., 2000) were further considered 
suitable targets for the study.  In addition, targets whose host ortholog’s disruption by a designed compound 
through non- specific drug interactions would be highly detrimental to the host were also not further considered 
for drug design. 
 
2.3 Target structure preparation 
Three dimensional structures of S.mansoni fatty acid binding protein were retrieved from the PDB and visualized 
using the Pymol molecular graphics program (Pymol.org, 2012). Co-crystalized ligand molecules in the 
downloaded structures were identified and used to define the target’s binding site. The 3D Ligand Site server 
(Wass et al., 2010) was used to identify the binding sites of any structures that had no ligands. 
 
2.4 Ligand preparation  
A library of ligands was generated from 755 carboxylic acids downloaded in MDL mol format (Dalby et al., 
1992) from LipidBank (Yasugi and Seyama, 2007). The MarvinSketch program (Chemaxon.com) was used to 
add explicit hydrogen atoms to these structures and subsequently to clean their 3-Dimensional structures. The 
open source program OpenBabel (O’Boyle et al., 2011) was used to convert the MDL mol structures of these 
molecules molecule into a single SDF file (Dalby et al., 1992). 
 
2.5 Library screening 
The Arguslab molecular docking software (Planaria Software LLC, 2004) was used to dock all ligands in the 
library to the target’s binding site through the programs implementation of the ArgusDock exhaustive search 
docking engine. All ligands were treated as flexible molecules and evaluated for ligand-target interaction 
energies using the software’s in-built Ascore scoring function. The search space was automatically calculated by 
Arguslab and grids of resolution 0.4 angstroms were generated and used in the docking run.  
 
2.6 Lead identification 
Only ligands with estimated interactions energies lower than that of the co-crystallized ligands i.e. Oleic acid 
Arachidonic acid were selected from the library screening process as lead compounds.   
 
2.7 ADMET analysis 
The (Absorption, Distribution, Metabolism, Excretion and Toxicity) ADMET properties of each lead compound 
were estimated using the OSIRIS Property Explorer tool (Actelion Pharmaceuticals Ltd, 1999).  The structure of 
each compound was manually drawn on the tool’s java based web applet for on-the-fly calculations of the cLogP, 
solubility, molecular weight, drugscore, druglikeness and toxicity risks for mutagenic, tumorigenic, irritant and 
reproductive effective properties.   
 
2.8 Lead optimization 
Functional side groups were introduced on the lead compounds through hydrogen substitutions in a manner that 
improved the ADMET properties of each compound using the OSIRIS Property Explorer. The structures of all 
optimized compounds were generated and saved as MDL mol format files using ChemAxon’s Marvinsketch 
program.  
 
2.9 Nomenclature and docking of optimized compounds 
IUPAC names for optimized compounds were generated from their structures using Chemaxon’s Marvinsketch 
program.  The MDL mol structure files of these compounds were combined into a single SDF file using 
OpenBabel. This file was used as a ligand database for docking the optimized compounds into the binding site of 
the target protein to evaluate their interaction energy. 
 
2.10 Prediction of Biological activity 
The biological activity of optimized compounds that had lower interaction energy than arachidonic acid with the 
target protein was predicted using the Prediction of Activity Spectra for Substances (PASS) online server 
(Laguni et al., 2000). The MDL mol file of each compound was uploaded individually to the server for 
prediction. 
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3. Results  
3.1 Target selection and validation 
Ten S.mansoni genes were selected as possible antischistosomal drug targets through analysis of the parasite’s 
metabolic pathways in KEGG. These genes play crucial roles in the parasite and were deemed as good targets for 
drug action against the parasite as shown in Table 1. 
 
Table 1. Selected putative targets. 
Putative target KEGG accession Process PDB structure 
Ryanodine receptor Smp_101180 Muscle contraction - 
Mevalonate kinase Smp_042980 Mevalonate pathway - 
Phosphomevalonate kinase Smp_072460 Mevalonate pathway - 
Hexokinase Smp_043030 Glycolysis 1BDG 
Phosphopyruvate hydratase Smp_024110 Glycolysis - 
Hydroxymethylglutaryl CoA 
reductase 
Smp_138590 Mevalonate pathway - 
Methionyl aminopeptidase  
Smp_142010.2 
Smp_011120 
Protein degradome - 
Rab 6 Smp_176050 Cellular transport - 
Fatty acid binding protein Smp_095360.1 Fatty acid transport 1VYG, 1VYF, 
1POA 
Calmodulin Smp_018940 Phosphatidylinositol signaling 
system 
- 
 
 Despite the high viability of the selected proteins as drug targets in the parasite, we screened off those 
without experimentally determined structures as a measure of minimizing errors in docking that could arise from 
incorrect protein folding and incorrect orientation of binding site residues in modelled structures. Although a 
structure for hexokinase was present in the PDB, we avoided this target because of the high likelihood that a 
compound designed to disrupt its function would also disrupt mammalian hexokinase owing to the similar nature 
of substrate, binding sites and mechanism of catalysis between the two. Interference with glycolysis in 
mammalian host could cause variations in blood glucose levels that might be detrimental especially to 
individuals at high risk of glucose metabolism disorders. 
 
3.2 Target structure preparation 
Two crystallographic (1VYG and 1VYF) and one NMR (2POA) structures of S.mansoni fatty acid binding 
protein were retrieved from the PDB. The three structures were visualized in Pymol to reveal co-crystalized 
ligands: arachidonic acid and oleic acid in 1VYG and 1VYF respectively, whereas the structure 2POA did not 
have any ligand (Figure1). 
 
Figure 1: Structures of target protein as visualized in Pymol. A: IVYG with arachidonic acid visible in the 
protein’s binding site. B: IVYF with oleic acid visible in the binding site. C: 2POA with no ligand. The ribbon 
structures are colored red through blue from the carboxylic to the amino terminal ends. The molecular surfaces 
of the protein are also shown with similar coloring of residues along the chain. 
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3.3 Binding site selection 
The Pymol program was also used to identify binding site residues in the structures. Residues in the binding site 
of oleic acid in the structure 1VYF were PHE16, VAL19, MET20, LEU23, VAL25, THR29, ILE32, GLY33, 
VAL36, PRO38, THR53, GLU54, PHE57, LYS58, SER75, ASP76, ARG78, GLN96, THR103, ILE105, 
ARG107, THR116, VAL118, ARG127 andTYR129 while the same residues were also in the binding site of 
arachidonic acid in the structure 1VYG with an addition of LEU 60 (Figure 2).  Binding site residues in 2POA 
were predicted by the 3D Ligand Site Server as follows: 16PHE, 23LEU, 35VAL, 28ALA, 29THE, 30ARG, 
32ILE, 33GLY, 36VAL, 51MET, 57PHE, 58LYS, 62VAL, 70PHE, 72GLU, 74THR, 75SER, 76ASP, 78ARG, 
84VAL, 94GLN, 96GLN, 98ASP, 103THR, 105ILE, 107ARG and 127ARG. More than 60 percent of these 
residues were common for all the three ligands and occur in the same cavity in the target protein.  The binding 
site of arachidonic acid in the structure 1VYG was set up for all docking calculations. 
 
Figure 2: Binding site residues in 1VYG. Arachidonic acid is rendered as stick while amino acid residues are 
rendered as wireframe. Hydrogen bonds are shown as black dotted lines and water molecules as red crosses. 
 
3.4 Library screening 
A total of 35 out of the 755 carboxylic acids screened consistently showed lower interaction energy than 
arachidonic acid with the S.mansoni fatty acid binding protein and were selected as lead compounds (Table 2).  
 
3.5 ADMET analysis 
Each of the selected lead compounds was evaluated for various ADMET properties using the OSIRIS property 
explorer as shown in Table 2. 
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Table 2: Binding energy and predicted ADMET properties of the selected lead compounds. 
LipidBank 
Id. 
Interaction 
energy 
Kcal/mol 
cLogP Solubility Molecular 
weight 
Drug 
likeness 
Drug 
score 
Toxicity risk 
DFA0024 -13.9093 10.23 -6.4 368 -25.22 0.14 none 
DFA0025 -14.0123 10.7 -6.67 382 -25.22 0.13 none 
DFA0026 -14.0975 11.16 -6.94 396 -25.22 0.13 none 
DFA0030 -14.584 13.02 -8.02 452 -25.22 0.11 none 
DFA0031 -14.6176 13.48 -8.29 466 -25.22 0.1 none 
DFA0032 -15.9191 13.95 -8.56 480 -25.22 0.1 none 
DFA0033 -15.0982 14.41 -8.83 494 -25.22 0.1 none 
DFA0034 -15.7452 14.87 -9.1 508 -25.22 0.09 none 
DFA0035 -16.4189 15.34 -9.37 522 -25.22 0.09 none 
DFA0036 -17.1863 15.8 -9.64 536 -25.22 0.09 none 
DFA0037 -16.0922 16.27 -9.91 550 -25.22 0.09 none 
DFA0038 -16.4506 16.73 -10.18 564 -25.22 0.08 none 
DFA0132 -14.4781 9.88 -6.17 366 -28.97 0.14 none 
DFA0133 -14.5945 10.8 -6.71 394 -28.97 0.13 none 
DFA0134 -14.3868 10.8 -6.71 394 -28.97 0.14 none 
DFA0135 -14.4871 11.73 -7.25 422 -28.97 0.12 none 
DFA0136 -14.8182 12.66 -7.79 450 -28.97 0.11 none 
DFA0137 -15.2025 13.59 -8.33 478 -28.97 0.1 none 
DFA0170 -13.9464 8.59 -5.4 336 -24.85 0.17 none 
DFA0213 -13.7482 6.95 -4.41 304 -10.1 0.22 none 
DFA0216 -14.5648 7.87 -4.95 332 -23.27 0.19 none 
DFA0217 -14.6828 7.87 -4.95 332 -25.56 0.19 none 
DFA0218 -14.4056 7.87 -4.95 332 -20.74 0.11 irritant 
DFA0219 -14.0697 6.59 -4.18 302 -8.9 0.19 moderate risk irritant 
DFA0221 -14.7107 7.52 -4.72 330 -17.53 0.2 none 
DFA0222 -14.6792 7.52 -4.72 330 -10.83 0.12 high risk irritant 
DFA0223 -14.8789 7.52 -4.72 330 -20.74 0.12 High risk irritant 
DFA0224 -14.3433 7.16 -4.49 328 -10.83 0.13 High risk irritant 
DFA0225 -15.3845 8.09 -5.03 356 -10.83 0.11 High risk irritant 
DFA0247 -13.7912 10.79 -6.61 396 -13.29 0.13 none 
DFA0253 -14.6216 13.36 -8.18 466 -11.17 0.1 none 
DFA0257 
-14.4959 
11.03 -6.62 408 -16.9 0.06 high risk mutagenic, 
moderate risk 
reproductive effective 
DFA8086 
-14.0613 
6.04 -4.33 336 -13.28 0.05 high risk mutagenic, 
tumorigenic and irritant 
DFA8133 -13.8034 5.93 -4.01 320 -17.88 0.26 none 
DFA8157 -14.1638 5.85 -4.06 318 -17.13 0.27 none 
 
3.6 Lead optimization 
Several compounds (Table 3) were generated through hydrogen group substitutions on the lead compounds. 
Substitution of hydrogen atoms at various positions in the structures of lead compounds was guided by the 
overall effect that each substitution produced on the compounds’ ADMET properties. The best possible 
properties attained for the optimized compounds are shown in Table 4. In addition, the topological polar surface 
area of each compound was calculated using Chemaxon’s Marvinsketch program (Table4). These compounds 
were docked to the target protein to evaluate their interaction energies (table 5). The IUPAC names for the 
optimized compounds are shown in table 5. 
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Table 3: Structures of compounds generated from lead optimization. 
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Table 4: Predicted ADMET properties of generated compounds. 
lead Derived 
compound 
cLogP Solubility Molecular 
weight 
Drug 
likeness 
Drug 
score 
Toxicity 
risk 
TPSA 
DFA0225 d, e,  f, g, h, p, 
q 
3.97 -3.99 402 -4.61 0.34 none 109.57 
DFA0223  j 3.4 -3.67 376 -1.49 0.44 none 109.57 
DFA0223 i 2.86 -3.75 375 -1.94 0.43 none 115.36 
DFA0223 t 3.93 -3.6 377 -0.63 0.48 none 103.78 
DFA0221 l 4.95 -4.0 361 -4.07 031 none 83.55 
DFA0217 n 4.58 -4.63 396 -4.81 0.29 none 89.34 
DFA0217 m 4.77 -4.3 362 -7.02 0.3 none 89.34 
DFA0222 k 4.95 -4.0 361 -4.58 0.3 none 83.55 
DFA0224 s 2.56 -2.97 391 -0.68 0.54 none 124.01 
FA8157 a 3.28 -3.34 349 -3.86 0.4 none 100.62 
DFA0219 v 4.61 -3.86 332 -6.7 0.33 none 89.34 
DFA8086 c 3.68 -4.38 400 -2.81 0.35 none 118.8 
DFA8086 b 2.58 -3.7 381 -3.01 0.41 none 144.82 
DFA0213 r 4.38 -3.69 335 -3.92 0.35 none 83.55 
DFA0213 o 4.3 -5.51 451 -14.66 0.24 none 115.36 
DFA0218 u 4.29 -3.83 379 -4.35 0.34 none 103.78 
 TPSA-Topological Polar Surface Area 
 
Table 5: IUPAC naming and interaction energies of generated compounds. 
Compound IUPAC Name Interaction energy 
a (4S,5Z,8Z,10E,14Z,18R)-18-amino-4-hydroxy-12-oxoicosa-5,8,10,14-
tetraenoic acid 
-12.9082 
b (3R,5Z,8E,11Z,14S,15Z,19R)-9,19-diamino-14-(aminooxy)-3-hydroxyicosa-
5,8,11,15-tetraenoic acid 
-12.692 
c (3R,5Z,8E,11Z,14S,15Z,19R)-19-amino-14-(aminooxy)-9-chloro-3-
hydroxyicosa-5,8,11,15-tetraenoic acid 
-12.5987 
d (3S,4E,8E,12E,15E,18E,20S,21E,23S)-20,23-diamino-3-hydroxytetracosa-
4,8,12,15,18,21-hexaenoic acid 
-15.5521 
e (3S,4E,8E,11S,12E,15E,18E,21E,23S)-11,23-diamino-3-hydroxytetracosa-
4,8,12,15,18,21-hexaenoic acid 
-14.6348 
f (3S,4E,8E,10R,12E,15E,18E,21E,23S)-10,23-diamino-3-hydroxytetracosa-
4,8,12,15,18,21-hexaenoic acid 
-15.44 
g (3S,4E,7S,8E,12E,15E,18E,21E,23S)-7,23-diamino-3-hydroxytetracosa-
4,8,12,15,18,21-hexaenoic acid 
-14.5169 
h (3S,4E,6R,8E,12E,15E,18E,21E,23S)-6,23-diamino-3-hydroxytetracosa-
4,8,12,15,18,21-hexaenoic acid 
-13.7576 
i (3S,5R,7Z,10Z,13Z,16Z,19Z,21R)-3,5,21-triaminodocosa-7,10,13,16,19-
pentaenoic acid 
-13.4618 
j (3S,5R,7Z,10Z,13Z,16Z,19Z,21R)-3,21-diamino-5-hydroxydocosa-
7,10,13,16,19-pentaenoic acid 
-13.5923 
k (3S,4Z,8Z,12Z,15Z,19Z,21R)-21-amino-3-hydroxydocosa-4,8,12,15,19-
pentaenoic acid 
-13.8649 
l (3S,4Z,7Z,10Z,13Z,16Z,20S)-20-amino-3-hydroxydocosa-4,7,10,13,16-
pentaenoic acid 
-13.5934 
m (4R,7Z,10Z,13Z,16Z,20S)-4,20-diaminodocosa-7,10,13,16-tetraenoic acid -13.4261 
n (3R,4S,7Z,10Z,13Z,16Z,20S)-4,20-diamino-3-chlorodocosa-7,10,13,16-
tetraenoic acid 
-13.5759 
o (2S,5E,8E,11E,14Z,17R,18R)-2,17,18-triamino-6,8,12-trichloroicosa-
5,8,11,14-tetraenoic acid 
-13.4181 
p (3S,4E,8E,12E,15E,17S,18E,21E,23S)-17,23-diamino-3-hydroxytetracosa-
4,8,12,15,18,21-hexaenoic acid 
-14.6651 
q (3S,4E,8E,12E,14R,15E,18E,21E,23S)-14,23-diamino-3-hydroxytetracosa-
4,8,12,15,18,21-hexaenoic acid 
-15.8855 
r (3R,5Z,8Z,11Z,14Z,18S)-18-amino-3-hydroxyicosa-5,8,11,14-tetraenoic acid -13.4304 
s (3S,4Z,7Z,9R,10Z,12S,13Z,16Z,19Z,21R)-21-amino-3,9,12-trihydroxydocosa-
4,7,10,13,16,19-hexaenoic acid 
-13.2826 
t (3S,5R,7Z,10Z,13Z,16Z,19Z)-5-amino-3,21-dihydroxydocosa-7,10,13,16,19-
pentaenoic acid 
-13.0026 
u (3S,6R,8Z,12Z,16Z,19Z,21R)-21-amino-3,6-dihydroxydocosa-8,12,16,19-
tetraenoic acid 
-13.3608 
v (3R,4Z,8Z,12Z,15Z,18E)-3,19-diaminoicosa-4,8,12,15,18-pentaenoic acid -12.8736 
Journal of Biology, Agriculture and Healthcare                                                                                                                                www.iiste.org 
ISSN 2224-3208 (Paper)  ISSN 2225-093X (Online) 
Vol.4, No.19, 2014 
 
19 
3.8 Biological Activity Prediction 
Generated compounds that had lower interaction energy than arachidonic acid were selected as potential 
competitive inhibitors of the target protein. Their likely biological activities were predicted for numerous 
categories evaluated by the PASS server. The two likely biological activities predicted with highest probability 
values for these compounds is shown in Table 6. 
 
Table 6: Predicted biological activities of compounds with low interaction energies. 
Compound Pa Pi Biological Activity 
d, k, p and q 0.932 0.003 Beta-adrenergic receptor kinase inhibitor 
 0.932 0.003 G-protein-coupled receptor kinase inhibitor 
e, f, g, and h 0,909 0,004 Beta-adrenergic receptor kinase inhibitor 
 0,909 0,004 G-protein-coupled receptor kinase inhibitor 
Pa- probability of being active, Pi- probability of being inactive 
 
4. Discussion 
Schistosomes are incapable of de novo synthesis of sterols or free fatty acids and must use complex precursors 
from the host (Brouwers et al., 1997). S.mansoni fatty acid binding protein was selected as a putative target that 
can be inhibited to block the parasite’s mechanism of reliance on the host for fatty acid biosynthesis. 
Coincidentally, this protein has been studied as a target for vaccine development because it possesses cross-
reactive, discontinuous epitopes principally derived from amino acids in the C-terminal portions of its structure 
(Ramos et al., 2009). Inhibiting this protein would hamper synthesis of cell membranes and protein modification 
of the parasite which depend on uptake and transport of fatty acids from the host. There is minimal probability of 
producing adverse effects in the host through non-specific interaction of an inhibitor of this protein with host 
orthologs. It has been reported that pharmacologically blocking adipocyte fatty acid binding protein in mice 
alleviates both acute liver injury and non-alcoholic steatohepatitis (Hoo et al., 2012). Similarly, inhibiting fatty-
acid-binding protein 4 (Adipocyte protein 2) has been found to treat diabetes and atherosclerosis in mouse 
models (Furuhashi et al., 2004). However, the nature of effects produced by the designed novel drug compounds 
need to be ascertained through testing in animal models.  
 Docking calculations revealed that arachidonic acid interacts more readily with the target protein than 
oleic acid. The two fatty acids had interaction energies of -13.7482kcal/mol and -12.6204 kcal/mol respectively 
in the library screening docking run. This observation is coherent with previous findings (Angelucci et al., 2004) 
which suggested that the target protein’s binding site is optimized to fit arachidonic acid. We therefore used 
arachidonic acid as a reference ligand and screened for compounds with the ability to interact more readily with 
the protein.  Out of the 35 carboxylic acids that had lower interaction energies than arachidonic acid, only 11 
could sufficiently be optimized to conform to a pharmacophore model. Those with molecular weights greater 
than 450 were screened out in line with the observation that 80% of all traded drugs have a molecular weight less 
than 450 daltons (Actelion Pharmaceuticals Ltd, 1999) whereas it was not possible to generate optimized 
compounds for the rest  without violating one or more of Lipinski’s rule of five (Lipinski, 2004). Eight 
optimized compounds were found to interact with the target protein at lower binding energy than arachidonic 
acid through docking, suggesting a capability to inhibit this protein. The eight compounds: d, e, f, g, h, k, p and q 
can be deduced to be orally active and well absorbed by passive diffusion across cell membranes because they 
comply with all criteria of the Lipinski’s rule of five. In addition, the topological polar surface areas of all the 
eight compounds is well below 140 Å 2 inferring ability to permeate cell membranes and intestinal mucosa. 
These compounds are however unlikely to cross the blood brain barrier because their topological polar surface 
areas are above 70Å2, which is a good property because none of the parasitic stages of schistosomes get localized 
in the central nervous system. The predicted aqueous solubility values of these compounds are at the lower 
bounds when compared to majority of traded drugs which have values greater than -4 (Actelion Pharmaceuticals 
Ltd, 1999). However, measures to increase solubility could be employed if bioavailability of the drug at a 
determined dosage is found to be low. Such methods include micronization (Bladgen et al., 2007), 
nanosuspension (Muller et al., 2000), preparation of binary eutectic mixtures (Liu et al., 2006), solid dispersion 
(Sekiguchi and Obi, 1961) and hydrotrophy (Roy and Moulik, 2002). The PASS online server predicted 
numerous possible biological activities for the eight compounds. The highest probability predicted for all the 
eight compounds was the inhibition of beta-adrenergic receptor kinase. This inhibition has been employed to 
reverse cardiac dysfunction in failing cardiomyocytes (Eckhart and Koch 2002) and therefore would not present 
a major challenge as an adverse effect in a mammalian host body system. Similarly, these compounds were 
predicted with high probability to have inhibitory activity on G-protein-coupled receptor kinase, an activity that 
has been shown to have cardioprotective effects (Fu et al., 2013).  However, the actual biological activity that 
any of these compounds possess can only be ascertained experimentally especially considering the possibility 
that pharmacological activity may be destroyed in first pass metabolism. 
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 The success of computational drug design cannot be fully appreciated unless complemented by 
experimental testing. Theoretical concepts and ideological premises employed in in silico drug design have to be 
evaluated for experimental evidence of drug activity and associated effects for the drug to be useful towards its 
intended purpose. The novel compounds d, e, f, g, h, k, p and q can therefore be synthesized and tested in vitro 
for activity against schistosomes as well as in animal models for efficacy and biological activity. In addition, 
these compounds can also be synthesized and tested in animal models for their predicted inhibitory activity on 
Beta-adrenergic receptor kinase and G-protein-coupled receptor kinase in order to evaluate their possible use in 
cardioprotective strategies. 
 
5. Conclusion 
The S.mansoni genome has a promising potential of presenting novel drug targets that can be exploited for anti-
schistosomal drug design. Alternative drug development for schistosomiasis is necessary to alleviate over-
reliance on praziquantel and also to mitigate against limitations in therapeutic management of the disease should 
the parasites develop resistance to praziquantel.  In the present study, a few key targets in the parasite have been 
evaluated and eight novel compounds with potential to competitively inhibit the S.mansoni fatty acid binding 
protein designed. These compounds can therefore be evaluated as candidate drug compounds in strategy to 
incapacitate the parasite from proper utilization of fatty acids from the host. Although theoretical and 
computational evidence suggest good anti-schistosomal prospects for these compounds, in vitro and in vivo 
testing for activity and efficacy are the surest means of ascertaining their contribution to anti-schistosomal drug 
discovery and development. These compounds can therefore be synthesized and tested experimentally for their 
pharmacological activity. 
 
References 
Actelion Pharmaceuticals Ltd, OSIRIS Property Explorer (1999). Available from: <http://www. organic-
chemistry.org/prog/peo/>. [03-10-2013]. 
Amin M.A., Elbakry A., Zayed G. and Zaky A. (2013). Preparation and Evaluation of Nanosuspension for 
Poorly Soluble Drug to Improve the In Vitro and In Vivo Efficacy. Journal of Life Medicine, 1(3) 99-107. 
Angelucci F.,  Johnson K.A.,  Baiocco P., Miele A.E., Brunori M.,  Valle C., Vigorosi F.,  Troiani A.R., Liberti 
P., Cioli D.,  Klinkert M.Q. and Bellelli A. (2004). Schistosoma mansoni fatty acid binding protein: specificity 
and functional control as revealed by crystallographic structure. Biochemistry, 43(41):13000-11 
Berman H.M., Westbrook J., Feng Z., Gilliland G., Bhat T.N., Weissig H., Shindyalov I.N., Bourne P.E. (2000). 
"The Protein Data Bank. Nucleic Acids Research, 28 (1): 235–242 
Berriman M., Haas B.J., LoVerde P.T. and Wilson R.A. (2009). The genome of the blood fluke Schistosoma 
mansoni. Nature, 460 (7253):352-8. 
Blagden N., de Matas M., Gavan P.T. and York P. (2007). Crystal engineering of active pharmaceutical 
ingredients to improve solubility and dissolution rates. Advanced Drug Delivery Reviews, 59 (7):617–630 
Brouwers J.F., Smeenk I.M., van Golde L.M. and Tielens A.G. (1997). The incorporation, modification and 
turnover of fatty acids in adult Schistosoma mansoni. Molecular and Biochemical Parasitology, 88: 175–185 
Chemaxon.com, Marvin 5.7.2 (2012). Available from <http://www.chemaxon.com>. [27-01-2013].  
Couto F.B., Coelho P.M., Araújo N., Kusel J.R., Katz N., Jannotti-Passos L.K. and Mattos A.C.(2011). 
Schistosoma mansoni: a method for inducing resistance to praziquantel using infected Biomphalaria 
glabrata snails. Memórias do Instituto Oswaldo Cruz, 106(2):153-157 
Crowther G.J., Shanmugam D., Carmona S.J., Doyle M.A., Hertz-Fowler C et al., (2010). Identification of 
Attractive Drug Targets in Neglected-Disease Pathogens Using an In Silico Approach. PLoS Neglected Tropical 
Diseases, 4(8): e804 
Dalby A., Nourse J.G., Hounshell W.D., Gushurst A.K., Grier D.L., Leland B.A. and Laufer J. (1992). 
"Description of several chemical structure file formats used by computer programs developed at Molecular 
Design Limited". Journal of Chemical Information and Modeling, 32 (3): 244 
Eckhart A.D. and Koch W.J. (2002). Expression of a beta-adrenergic receptor kinase inhibitor reverses 
dysfunction in failing cardiomyocytes. Journal of Molecular Therapy, 5(1):74-9 
Fu X., Koller S., Alla J.A. and Quitterer U. (2013). Inhibition of G-protein-coupled receptor kinase 2 (GRK2) 
triggers the growth-promoting mitogen-activated protein kinase (MAPK) pathway. Journal of biological 
chemistry, 288(11):7738-55. 
Furuhashi M., Tuncman G., Görgün C.Z., Makowski L., Atsumi G., Vaillancourt E., Kono K.,  Babaev B.R., 
Fazio S., Linton M.F., Sulsky R., Robl J.A., Parker R.A. and Hotamisligil G.S. (2007). Treatment of diabetes 
and atherosclerosis by inhibiting fatty-acid-binding protein aP2. Nature, 447:959-965 
Hoo R.L., Lee I.P., Zhou M., Wong J.Y., Hui X., Xu A. and Lam K.S. (2012). Pharmacological inhibition of 
adipocyte fatty acid binding protein alleviates both acute liver injury and non-alcoholic steatohepatitis in mice. 
Hepatology, 58(2): 358-364 
Journal of Biology, Agriculture and Healthcare                                                                                                                                www.iiste.org 
ISSN 2224-3208 (Paper)  ISSN 2225-093X (Online) 
Vol.4, No.19, 2014 
 
21 
Kanehisa M., Goto S., Sato Y., Furumichi M. and Tanabe M. (2012). KEGG for integration and interpretation of 
large-scale molecular datasets. Nucleic Acids Research, 40: 109-114  
Lagunin A., Stepanchikova A., Filimonov D. and Poroikov V. (2000). PASS: prediction of activity spectra for 
biologically active substances. Bioinformatics. 16 (8): 747-748. 
Lipinski C.A. (2004). "Lead- and drug-like compounds: the rule-of-five revolution". Drug Discovery Today: 
Technologies, 1 (4): 337–341 
Liu D., Fei X. and Wang S. (2006). Increasing solubility and dissolution rate of drugs via eutectic mixtures: 
itraconazole–poloxamer188 system. Asian journal of Pharmaceutical Sciences, 1(3-4): 213-221 
Melman S.D., Steinauer M.L., Cunningham C., Kubatko L.S. and Mwangi I.N. (2009). Reduced Susceptibility 
to Praziquantel among Naturally Occurring Kenyan Isolates of Schistosoma mansoni. PLoS Neglected Tropical 
Diseases, 3(8): e504 
O'Boyle N.M., Banck M., JamesC.A., Morley C., Vandermeersch T. and Hutchison G.R. (2011). Open Babel: 
An open chemical toolbox. Journal of Cheminformatics, 3: 33. 
Planaria Software LLC, Arguslab 4.0.4 (2004). Available from: <http://www.arguslab.com>. [10-01-2012]. 
Pymol.org, Pymol 1.5 (2012). Available from: <http://www.pymol.org>. [21-03-2012]. 
Ramos C.R., Spisni A., Oyama S., Sforça M.L., Ramos H.R., Vilar M.M., Alves A.C., Figueredo R.C., Tendler 
M., Zanchin N.I., Pertinhez T.A. and Ho P.L. (2009). 
 Stability improvement of the fatty acid binding protein Sm14 from S. mansoni by Cys replacement: structural 
and functional characterization of a vaccine candidate. Biochimica et Biophysica Acta, 1794(4):655-62 
Roy B.K. and Moulik S.P. (2002). Functions of hydrotropes (sodium salicylate, proline, pyrogallol, resorcinol 
and urea) in solution with special reference to amphiphile behaviors. Colloids and surfaces A-physicochemical 
and engineering aspects, 203(1–3):155–166. 
Sekiguchi K., and Obi N. (1961). Studies on absorption of eutectic mixtures. I.A. comparison of the behaviour of 
eutectic mixtures of sulphathiazole and that of ordinary sulphathiazole in man. Chemical and Pharmaceutical 
Bulletin, 9:866–872. 
Steinmann P., Keiser J., Bos R., Tanner M., and Utzinger J. (2006). Schistosomiasis and water resources 
development: systematic review, meta-analysis, and estimates of people at risk. Lancet Infectious Diseases, 6: 
411–425.  
Wass M.N., Kelley L.A. and Sternberg M.J. (2010). 3DLigandSite: predicting ligand-binding sites using similar 
structures. Nucleic Acids Research, 38 Suppl: W469-73 
Yasugi E. and Seyama Y. (2007). Lipid database "LipidBank" and international collaboration. Tanpakushitsu 
Kakusan Koso, 52(11):1357-62 
 
  
The IISTE is a pioneer in the Open-Access hosting service and academic event 
management.  The aim of the firm is Accelerating Global Knowledge Sharing. 
 
More information about the firm can be found on the homepage:  
http://www.iiste.org 
 
CALL FOR JOURNAL PAPERS 
There are more than 30 peer-reviewed academic journals hosted under the hosting 
platform.   
Prospective authors of journals can find the submission instruction on the 
following page: http://www.iiste.org/journals/  All the journals articles are available 
online to the readers all over the world without financial, legal, or technical barriers 
other than those inseparable from gaining access to the internet itself.  Paper version 
of the journals is also available upon request of readers and authors.  
 
MORE RESOURCES 
Book publication information: http://www.iiste.org/book/ 
 
IISTE Knowledge Sharing Partners 
EBSCO, Index Copernicus, Ulrich's Periodicals Directory, JournalTOCS, PKP Open 
Archives Harvester, Bielefeld Academic Search Engine, Elektronische 
Zeitschriftenbibliothek EZB, Open J-Gate, OCLC WorldCat, Universe Digtial 
Library , NewJour, Google Scholar 
 
 
